IKT Inhibikase Therapeutics, Inc. Stock Quote

IKT [NASD]

Index	-	P/E	-	EPS (ttm)	-0.55	Insider Own	52.40%	Shs Outstand	10.05M	Perf Week	13.23%
Market Cap	62.00M	Forward P/E	-	EPS next Y	-0.78	Insider Trans	0.00%	Shs Float	4.79M	Perf Month	11.53%
Income	-4.90M	PEG	-	EPS next Q	-	Inst Own	16.50%	Short Float	1.30%	Perf Quarter	-6.50%
Sales	1.80M	P/S	34.44	EPS this Y	43.30%	Inst Trans	1.72%	Short Ratio	1.91	Perf Half Y	-
Book/sh	0.80	P/B	7.44	EPS next Y	-	ROA	-69.30%	Target Price	-	Perf Year	-
Cash/sh	0.92	P/C	6.46	EPS next 5Y	-	ROE	-251.10%	52W Range	4.28 - 11.80	Perf YTD	-13.68%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-27.90%	52W High	-49.53%	Beta	-
Dividend %	-	Quick Ratio	3.30	Sales past 5Y	-	Gross Margin	-	52W Low	39.16%	ATR	0.44
Employees	3	Current Ratio	3.30	Sales Q/Q	366.70%	Oper. Margin	-	RSI (14)	58.98	Volatility	8.69% 8.99%
Optionable	No	Debt/Eq	0.15	EPS Q/Q	-348.40%	Profit Margin	-	Rel Volume	2.58	Prev Close	6.16
Shortable	Yes	LT Debt/Eq	0.03	Earnings	-	Payout	-	Avg Volume	32.57K	Price	5.96
Recom	-	SMA20	15.20%	SMA50	11.02%	SMA200	-4.62%	Volume	83,900	Change	-3.31%

May-25-21 08:00AM	Inhibikase Therapeutics to Present at Upcoming Jefferies Virtual Healthcare Conference & Others PR Newswire -6.66%
May-17-21 04:05PM	Inhibikase Therapeutics Reports First Quarter 2021 Financial Results and Highlights Recent Period Activity PR Newswire
Apr-21-21 08:00AM	Inhibikase Therapeutics to Present at Sachs 4th Annual Neuroscience Innovation Forum PR Newswire
Apr-01-21 08:00AM	Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period Activity PR Newswire
Mar-02-21 08:05AM	Inhibikase Therapeutics to Present at H.C. Wainwright & Co. Global Life Sciences Virtual Conference PR Newswire
Feb-22-21 08:05AM	Inhibikase Therapeutics to Present at the American Society of Experimental Neurotherapeutics (ASENT) Conference PR Newswire
Feb-17-21 12:48PM	Inhibikase Initiates Early-Stage Study Of Parkinson's Candidate Benzinga +10.78%
08:05AM	Inhibikase Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial of IkT-148009 to Treat Parkinsons Disease and Related Disorders Business Wire
Jan-04-21 08:01AM	Inhibikase Therapeutics Announces Partnership with Clintrex Research Corporation; C. Warren Olanow, MD, to Serve as Interim Chief Medical Officer PR Newswire
Dec-28-20 10:33AM	Inhibikase Therapeutics Announces Closing of Initial Public Offering PR Newswire
Dec-23-20 05:12PM	Inhibikase, GBS Both Fall Below IPO Price in First Trading Day Barrons.com
Dec-22-20 06:25PM	Inhibikase Therapeutics, Inc. Announces Pricing of its Initial Public Offering PR Newswire

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a c-Abl protein kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as dysphagia and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects. It is also developing IkT-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body. The company has collaborations with The Johns Hopkins University; Louisiana State University School of Medicine, Shreveport; and Memorial Sloan-Kettering Cancer Center. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Werner Milton H.	President and CEO	May 14	Option Exercise	0.38	43,707	16,609	5,288,645	May 18 05:46 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience